Richard Griffiths (SLN) reports 14.39M-share beneficial stake in Silence Therapeutics

Rhea-AI Filing Summary

Richard Griffiths filed Amendment No. 11 updating his beneficial ownership in Silence Therapeutics plc ordinary shares. He reports beneficial ownership of 14,391,498 ordinary shares, representing 7.97% of the class, based on 180,628,068 ordinary shares outstanding. These holdings consist of 10,777,044 shares represented by ADSs held by Ora Capital Limited, 600,000 shares represented by ADSs held by Cream Capital Limited, and 3,014,454 shares represented by ADSs held directly by Mr. Griffiths; each ADS represents three ordinary shares. The amendment states it is being filed to reflect significant dilution from an increase in the issuer’s share capital together with open market transactions in ADSs, including the sale by Mr. Griffiths of 5,484,320 ADSs in open market transactions between August 10, 2026 and August 12, 2026 for aggregate sales proceeds of $87.

Key Figures

Beneficial ownership: 14,391,498 ordinary shares Ownership percentage: 7.97% Shares outstanding: 180,628,068 ordinary shares +4 more

7 metrics

Beneficial ownership 14,391,498 ordinary shares Shares beneficially owned by Richard Griffiths following Amendment No. 11

Ownership percentage 7.97% Percent of Silence Therapeutics ordinary shares represented by 14,391,498 shares

Shares outstanding 180,628,068 ordinary shares Outstanding ordinary shares of Silence Therapeutics used to calculate ownership percentage

ADSs held by Ora Capital Limited 10,777,044 ordinary shares represented by ADSs Portion of Griffiths’ beneficial holdings via Ora Capital Limited

ADSs held by Cream Capital Limited 600,000 ordinary shares represented by ADSs Portion of Griffiths’ beneficial holdings via Cream Capital Limited

ADSs sold 5,484,320 ADSs Aggregate ADSs sold in open market transactions Aug 10–12, 2026

Aggregate sales proceeds $87 Total proceeds from sale of 5,484,320 ADSs between Aug 10 and Aug 12, 2026

Key Terms

beneficially owned, American Depositary Shares, sole voting power, sole dispositive power, +1 more

5 terms

beneficially owned financial

"Aggregate amount beneficially owned by each reporting person 14,391,498.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

American Depositary Shares financial

"ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

sole voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: Sole Voting Power 14,391,498.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: Sole Dispositive Power 14,391,498.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

dilution financial

"filed to reflect significant dilution as a result of an increase in the share capital"

Dilution occurs when a company issues additional shares, increasing the total number of shares outstanding. This can reduce the ownership percentage and voting power of existing shareholders, similar to slicing a pie into more pieces—each piece becomes smaller. For investors, dilution can mean a reduced stake in the company and potentially lower earnings per share, affecting the value of their investment.

FAQ

What ownership stake in Silence Therapeutics (SLN) does Richard Griffiths now report?

Richard Griffiths reports beneficial ownership of 14,391,498 ordinary shares of Silence Therapeutics, representing 7.97% of the company’s 180,628,068 outstanding ordinary shares, held directly and through Ora Capital Limited and Cream Capital Limited.

How are Richard Griffiths’ Silence Therapeutics (SLN) holdings structured?

His reported stake comprises 10,777,044 ordinary shares via ADSs held by Ora Capital Limited, 600,000 via ADSs held by Cream Capital Limited, and 3,014,454 via ADSs held directly. Each ADS represents three ordinary shares of Silence Therapeutics.

What recent trading activity in SLN ADSs did Richard Griffiths disclose?

Richard Griffiths disclosed selling an aggregate of 5,484,320 ADSs of Silence Therapeutics in open market transactions between August 10, 2026 and August 12, 2026, for aggregate sales proceeds of $87, as part of this ownership update.

Why was Amendment No. 11 filed regarding Silence Therapeutics (SLN)?

Amendment No. 11 was filed to reflect significant dilution resulting from an increase in Silence Therapeutics’ share capital, together with open market ADS transactions by Richard Griffiths that affected his reported beneficial ownership position.

What voting and dispositive power over SLN shares does Richard Griffiths report?

Richard Griffiths reports sole voting power and sole dispositive power over 14,391,498 ordinary shares of Silence Therapeutics and no shared voting or dispositive power, reflecting his control over the reported holdings.

What role do Ora Capital and Cream Capital play in SLN ownership for Richard Griffiths?

Ora Capital Limited holds 10,777,044 ordinary shares and Cream Capital Limited holds 600,000 ordinary shares via ADSs. Richard Griffiths is a director and controlling shareholder of both entities and can direct voting and disposition of these shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 09:55 PM Accepted by SEC EDGAR 08/13/2026 - 09:55 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 11)

Silence Therapeutics Plc

(Name of Issuer)

Ordinary Shares, nominal value of PS0.05 per share

(Title of Class of Securities)

G8128Y157

(CUSIP Number)

Richard Griffiths
19-21, Broad Street
St Helier, Y9, JE2 3RR
44 1534 517500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): G8128Y157

1

Name of reporting person

Richard Griffiths

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 14,391,498.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 14,391,498.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

14,391,498.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.97 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

* Consists of (i) 10,777,044 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 600,000 ordinary shares represented by ADSs held by Cream Capital Limited; and (iii) 3,014,454 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of both Ora Capital Limited and Cream Capital Limited and possesses the power to direct the voting and disposition of these shares. **This percentage is calculated based upon the 180,628,068 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, nominal value of PS0.05 per share
(b)	Name of Issuer: Silence Therapeutics Plc
(c)	Address of Issuer's Principal Executive Offices: 72 Hammersmith Road, London, UNITED KINGDOM , W14 8TH.
Item 1 Comment: This Amendment No. 11 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025, May 8, 2025, June 25, 2025 and 6 July 2026 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value PS0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect significant dilution as a result of an increase in the share capital of the Issuer together with open market transactions of the Issuer's ADSs by the Reporting Person. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D.
Item 2.	Identity and Background
(a)	Richard Griffiths
(b)	19-21 Broad Street, St Helier, Jersey, JE2 3RR
(d)	n/a
(e)	n/a
(f)	Jersey, Channel Islands
Item 3.	Source and Amount of Funds or Other Consideration
	Mr. Griffiths sold an aggregate of 5,484,320 ADSs in open market transactions between August 10, 2026 and August 12, 2026 for aggregate sales proceeds of $87.7M.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	n/a
Item 7.	Material to be Filed as Exhibits.
	Schedule 1 Transactions in ADSs During the Past Sixty Days

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Richard Griffiths

Signature:	/s/ Richard Ian Griffiths
Name/Title:	Director
Date:	08/13/2026